Gliflozins (SGLT-2 inhibitors) are novel antidiabetic agents that, in addition to lowering blood glucose, have a number of beneficial cardiovascular and reno-protective effects not only in people with diabetes but also in non-diabetic patients. However, the mechanism of their effects has not yet been fully elucidated. In addition, in patients with heart failure, they have significant effects on water and sodium distribution in the body, erythropoiesis, inter-organ iron distribution, hepatic steatosis (NAFLD), inflammation and oxidative stress. In genetic rat models of heart failure with preserved ejection fraction, we will analyze the effect of gliflozins on metabolic, renal and cardiovascular parameters. We will compare the effects of chronic treatment with gliflozins on heart failure in models with induced (high-fat diet) and genetic obesity compared to their non-obese controls.
